Bicara Therapeutics Reports Positive Phase 1b Data for Ficerafusp Alfa in HNSCC, Plans New Dosing Regimen

summarizeSummary

Bicara Therapeutics reported positive Phase 1b clinical data for its lead drug, ficerafusp alfa, in head and neck squamous cell carcinoma, showing strong efficacy and safety, and announced plans for a less frequent dosing regimen.

check_boxKey Events

• Positive Phase 1b Clinical Data Reported

  Preliminary safety and efficacy data from an exploratory Phase 1b expansion cohort for ficerafusp alfa (2000mg Q2W) in combination with pembrolizumab in 1L HPV-negative R/M HNSCC demonstrated rapid, deep, and durable responses.

• Strong Efficacy Metrics

  The data showed a 48% confirmed overall response rate (ORR) and a 26% complete response (CR) rate, with 77% of responders achieving deep responses of at least 80% tumor shrinkage.

• New Dosing Regimen Planned

  Based on the data, Bicara plans to develop ficerafusp alfa with a loading and every-three-week maintenance schedule, aiming for regulatory alignment to optimize efficacy, safety, and convenience.

• Consistent Safety Profile

  The 2000mg Q2W regimen was generally well-tolerated, with a safety profile consistent with previous findings for ficerafusp alfa plus pembrolizumab.

auto_awesomeAnalysis

Bicara Therapeutics announced compelling preliminary Phase 1b data for ficerafusp alfa, demonstrating rapid, deep, and durable responses in first-line HPV-negative recurrent/metastatic HNSCC. The data, which showed a 48% overall response rate and 26% complete response rate with a generally well-tolerated safety profile, supports the development of a less frequent, every-three-week maintenance dosing regimen. This positive clinical update reinforces the drug's differentiated mechanism of action and provides a strategic path for optimizing patient experience and outcomes, building on the company's previous announcement regarding Phase 3 dose selection for the same drug.